The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
Affiliation
KU Leuven
Country
Belgium
Current Status, Position
Prof Dr Steven Simoens is a Professor of health economics.
Education
Prof Dr Steven Simoens is a Commercial Engineer (KU Leuven, 1997), who later specialised in health economics and obtained a MSc in Health Economics (University of York, 1998) and a PhD in Economics (University of Aberdeen, 2001).
Research Area
The research interests of Steven Simoens focus on health economic aspects of medicinal products. Steven Simoens has carried out numerous cost(-of-illness) analyses, economic evaluations and budget impact analyses of medicinal products. He has also worked extensively in the area of policy relating to market access of medicinal products, with a particular interest in oncology, orphan, generic and biosimilar medicinal products, and shortages of medicinal products.
Conflict of interest: Prof Dr Steven Simoens is one of the founders of the KU Leuven Fund on Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL). He was involved in a stakeholder roundtable on biologics and biosimilars sponsored by Amgen, Pfizer and MSD, and participated in an advisory board meeting for Pfizer.
He contributed to studies on biologics and biosimilars for Hospira, Celltrion, Mundipharma and Pfizer and is member of the leadership team of the ISPOR Special Interest Group on Biosimilars.